Pipeline Insight: Cancer Overview Emerging Therapeutic and Commercial Opportunities

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2006-07-25

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The 11 tumor types covered in this report will account for over 2.3 million new cases of cancer in 2006 in the seven major pharmaceutical markets. Despite the emergence of targeted therapies, major unmet needs remain. NSCLC and breast cancer attract the highest R&D interest, but niche tumors with high unmet needs are gaining significant interest from pharmaceutical and biotech companies.


Scope

  • Overview of the 11 tumor types including current treatment options, unmet needs and product pipeline analysis.
  • Global sales forecasts and commercial potential with Datamonitor clinical and commercial drug assessment for Phase III agents to 2016.
  • Analysis of the global cancer market, identifying commonalities, major unmet needs and changing market and treatment trends.
  • Insight and commentary from qualitative interviews with oncology opinion leaders.


    • Report Highlights
    Advances in tumor understanding have initiated major R&D changes, with a resulting shift towards targeted therapies, which make up 44% of the current pipeline. As specific tumor pathways are targeted, fragmentation of the oncology market will occur as patient differentiation becomes based on malignant growth drivers rather than primary tumor site.

    Future cancer treatment will employ a multidisciplinary approach, incorporating the forthcoming influx of targeted therapies into current standard regimens. The cytotoxics and anti-hormonals markets will become increasingly genericized, although cost of treatment will continue to increase due to the incorporation of targeted therapies.

    The 'big four' tumor types (breast, prostate, NSCLC, colorectal) will remain the focus of R&D due to their high incidence, unmet needs and commercial potential. However, companies investing in niche markets such as pancreatic cancer will garner substantial benefits if an effective agent is developed, due to the current high level of unmet needs.


    Reasons to Purchase

  • Identify key drugs and companies within the oncology pipeline based on sales forecast to 2016 and Datamonitor drug assessment
  • Characterize unmet need and poorly served markets within oncology and assess the potential for pipeline agents to provide benefit
  • Assess the shifting oncology market dynamic and how future treatment and management of cancer patients will be affected

    • Table of Contents